Technology
The FLAIR Endovascular Stent Graft treats stenoses (narrowing) at the venous anastomosis of synthetic arteriovenous (AV) grafts in hemodialysis patients to increase blood flow.
October 16, 2007
News
October 17, 2007 - CryoCor, Inc., a medical device company focused on the treatment of cardiac arrhythmias, announced today that CryoCath Technologies Inc. has filed a lawsuit against CryoCor in the United States District Court for the District of Delaware alleging that CryoCor infringes several of CryoCath’s U.S. patents.
October 16, 2007
Technology
The Toshiba Aquilion CT line’s product platform design reportedly allows for all customers to benefit from Toshiba’s ...
October 16, 2007Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024News
October 17, 2007 - After a three-week trial, a jury rendered a verdict of "willful" patent infringement in a dispute filed against CHF Technologies, Inc., d/b/a BioVentrix, after Chase Medical sued BioVentrix alleging its Blue Egg Sizer, a hollow, blue silicone device used to guide surgeons in surgically resizing the heart, infringed patents held by Chase.
October 16, 2007
Technology
Agfa HealthCare’s DX-S reportedly fills the gap in the current range of Digital Radiography Solutions by providing a ...
October 16, 2007News
October 17, 2007 — The first trial to test whether medicated, drug-eluting (dispensing), stents can benefit patients who ...
October 16, 2007Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024
Feature | Maureen Leahy-Patano
The clinical definition of intraoperative awareness — consciousness during general anesthesia — is a seemingly simple explanation for a complex, and controversial, phenomenon. Opinions surrounding how often intraoperative awareness, also described as anesthesia awareness, occurs, its implications for victims, as well as the best methods for prevention are varied.
October 15, 2007News
October 16, 2007 – Medtronic Inc. said in a statement that it has voluntarily suspended worldwide distribution of the Sprint Fidelis family of defibrillation leads because of the potential for lead fractures, and the company recommends that physicians do no perform new implants of the leads (Sprint Fidelis Models: 6930, 6931, 6948, 6949).
October 15, 2007News
October 16, 2007 - Abiomed Inc. will be presenting clinical data on Impella 2.5 percutaneous Ventricular Assist Device ...
October 15, 2007Sponsored Content
Blog
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 11, 2023
Feature | Maureen Leahy-Patano
Safe medication administration at the hospital bedside is not simply a matter of a nurse handing out the right meds at the right time and to the right patient, of course. Today, the practice is a cooperative effort between the nursing staff and the pharmacy working to maximize the benefits of information technology solutions, such as bar coding and wireless.
October 15, 2007News
October 16, 2007 — In response to Medtronic’s decision to voluntarily suspend its Sprint Fidelis defibrillation leads, the Heart Rhythm Society (HRS) made a statement to underscore the importance of the society’s task force recommendations for the surveillance, analysis and performance reporting of pacemakers and implantable cardioverter defibrillators (ICDs).
October 15, 2007News
October 16, 2007 - MIV Therapeutics Inc., a developer of coatings and drug delivery systems for cardiovascular stents ...
October 15, 2007Sponsored Content
Case Study | Hemodynamic Monitoring Systems
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 14, 2023Feature | Christine Wyrick, M.D., Adebola Adesanya, M.D., Girish P. Joshi, MB BS, M.D., FFARCSI
Despite advances in our understanding of the pathophysiology of pain and the pharmacology of analgesic drugs, as well as increasing emphasis on adequate pain management [1], pain control remains inadequate in hospitalized patients.
October 15, 2007News
October 16, 2007 – Celera developed a five-gene genetic risk score based on five variant genes that predict risk for coronary heart disease (CHD), according to a study published in the October 2007 edition of Genetics in Medicine, marking the potential development of personalized disease management in the cardiovascular arena.
October 15, 2007
Technology
Siemens Medical Solutions Molecular Imaging Division's Symbia E series single photon emission computed tomography (SPECT ...
October 14, 2007© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now